TALWIN NX
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TALWIN NX is an oral small-molecule analgesic tablet approved in 1982 by Sanofi for pain management. The product's exact mechanism of action and indications are not fully documented in available data, but it represents a legacy pain treatment in the small-molecule category.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30%) suggests a contracting brand team and focus on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No current job openings are linked to TALWIN NX, reflecting its minimal commercial footprint and approaching LOE status. Career opportunities on this product are limited and focused on transition and wind-down management rather than growth.
Brand ManagerField Sales
Worked on TALWIN NX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.